Lilly(LLY)

Search documents
Eli Lilly (NYSE:LLY) Receives Overweight Rating from Cantor Fitzgerald with Increased Price Target
Financial Modeling Prep· 2025-10-09 17:05
Cantor Fitzgerald reaffirms its "Overweight" rating for Eli Lilly (NYSE:LLY), increasing its price target from $825 to $925.Eli Lilly partners with HealthTap to enhance its digital healthcare platform, LillyDirect, focusing on virtual diabetes management services.The addition of Peter Marks, a former top vaccine regulator, to Eli Lilly's team is expected to bolster the company's pharmaceutical innovations.Eli Lilly (NYSE:LLY) is a leading pharmaceutical company known for its innovative treatments and therap ...
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
ZACKS· 2025-10-09 15:16
Key Takeaways Lilly's Mounjaro and Zepbound drive half its revenues, fueling over 30% expected 2025 sales growth.AbbVie rebounds post-Humira LOE with Skyrizi and Rinvoq, targeting $25B in combined 2025 sales.2025 estimates for Lilly indicate 37% sales and 76.7% EPS growth, outpacing AbbVie's 7.6% and 18.9%.Eli Lilly (LLY) and AbbVie (ABBV) are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, robust R&D pipelines, strong market capitalization and global footprint. Bo ...
A Pricing Powerhouse, Now 30% Cheaper: Is Eli Lilly Stock A Buy?
Forbes· 2025-10-09 14:15
Photo illustration by Cheng Xin/Getty ImagesGetty ImagesEli Lilly (LLY) stock merits your attention. Why? Because it offers monopoly-like high margins at a reduced price. Here is some data.Revenue Growth: Eli Lilly experienced a growth of 36.8% LTM and an average of 23.4% over the last 3 years.Recent Profitability: Approximately 20.5% operating cash flow margin and 43.0% operating margin LTM.Long-Term Profitability: Roughly 17.8% operating cash flow margin and a 35.6% operating margin average over the last ...
医药生物行业双周报:2025ESMO大会召开在即:关注临床数据及基本面优异的公司-20251009
Great Wall Glory Securities· 2025-10-09 11:14
Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 2.72%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which declined by 2.62% [4][16] - The industry valuation as of September 30, 2025, is a PE (TTM overall method, excluding negative values) of 31.23x, down from 31.79x in the previous period, indicating a downward trend and below the average [21] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (55.74x), medical devices (41.29x), and hospitals (39.51x), with the median at 33.19x, while pharmaceutical circulation has the lowest valuation at 14.34x [21] Industry Review - The report highlights that during the reporting period, 51 listed companies in the pharmaceutical and biotechnology sector had a net reduction in shareholders amounting to 2.435 billion yuan, with 14 companies increasing their holdings by 681 million yuan and 37 companies reducing their holdings by 3.116 billion yuan [4] - The report emphasizes the importance of upcoming clinical data and the strong fundamentals of companies ahead of the ESMO 2025 conference, which is expected to showcase significant clinical research results from various domestic pharmaceutical companies [7][8] Important Industry News - AstraZeneca plans to list on the New York Stock Exchange [6] - The report mentions the approval of a new oral SERD drug by Eli Lilly, marking it as the second such drug approved globally [8][45] - The approval of the first domestic quadrivalent HPV vaccine in China is expected to expand the coverage population and potentially be priced lower than imported versions [8][50][52]
Guggenheim Raises Eli Lilly Price Target To $948, Cites Strong Mounjaro Trends
Financial Modeling Prep· 2025-10-08 20:15
Core Viewpoint - Guggenheim has raised its price target for Eli Lilly & Co. to $948.00 from $875.00 while maintaining a Buy rating, reflecting positive expectations for the company's upcoming financial performance [1] Group 1: Sales Forecasts - Mounjaro sales are projected to reach $5.49 billion for the quarter, slightly above consensus estimates of $5.43 billion, with $3.50 billion expected from the U.S. market [1] - For Zepbound, U.S. sales are projected at $3.35 billion, compared to Street expectations of $3.42 billion [2] - Overall third-quarter sales for Eli Lilly are forecasted at $16.06 billion, with earnings per share estimated at $6.32, broadly in line with consensus of $6.35 [2] Group 2: Market Dynamics and Growth Potential - Analysts noted potential variability in quarterly results due to pricing dynamics, international launches, and rebate adjustments, but they maintain confidence in Eli Lilly's long-term growth trajectory [3] - Key catalysts for future growth include ongoing developments in orforglipron filings, retatrutide trials, and the upcoming readout for Alzheimer's drug Kisunla [3]
Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875
Yahoo Finance· 2025-10-08 14:02
Eli Lilly & Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy According to Reddit, supported by hedge fund interest. Guggenheim Reaffirms Its Buy Rating on Eli Lilly & Company (LLY) with Price Target of $875 Eli Lilly & Company (NYSE:LLY) gained attention on September 29 when Guggenheim reaffirmed its Buy rating with a price target of $875. The analyst noted that there was strong demand for tirzepatide in the treatment of diabetes and obesity and that the impending launch of orforglipron w ...
HealthTap joins Lilly's online platform to offer diabetes management services
Reuters· 2025-10-08 12:03
Telehealth company HealthTap said on Wednesday it is joining Eli Lilly's digital healthcare platform, LillyDirect, to offer virtual diabetes management services. ...
These 2 AI Stocks Could Surpass Oracle in Market Cap by 2030
Yahoo Finance· 2025-10-08 10:31
This is why investors looking at Oracle might want to consider a couple of alternatives instead. There are two companies, in particular, that have performance potential that could help them grow faster than Oracle and even surpass Oracle's $801 billion market capitalization by 2030.Oracle's excessive dependence on a few massive contracts, such as its $300 billion deal with OpenAI, also exposes it to a high degree of counterparty risk. If OpenAI changes architectures or pivots away from Oracle Cloud, it coul ...
美国FDA前新冠疫苗负责人马克斯加入礼来
Di Yi Cai Jing· 2025-10-08 05:01
第一财经记者从接近礼来方面人士处证实,美国FDA生物制品评估与研究中心 (CBER) 前负责人彼得· 马克斯(Peter Marks)已加入礼来,担任分子发现高级副总裁兼传染病负责人。 担任分子发现高级副总裁兼传染病负责人。 在新冠疫情期间,马克斯曾负责美国新冠疫苗策略。今年4月,因与美国卫生部长小罗伯特·肯尼迪 (RFK Jr.) 就疫苗政策发生冲突,马克斯被迫离职。(第一财经记者 钱童心) ...